Topic resource collection
Approved comparison material connected to this topic.
5 resourcesRead both sides
Thymosin-alpha-1 TLR2 agonist, cytokine upregulation Th1 response, dendritic cell activation Subcutaneous injection 1.6–3.2 mg twice weekly Gold standard for immune modulation research. Strongest clinical trial evidence for viral…
Before selecting a peptide protocol, understand what each compound actually does. Not what marketing claims suggest. Thymosin Alpha-1 TLR activation → IL-2 upregulation T-cells (CD4+, Treg) 1.6mg subcutaneous 2x/week 4–8 weeks Go…
The table below compares immune-modulating peptides by pathway, target tissue, and documented research outcomes. Thymalin Upregulates thymulin production in thymic epithelial cells Thymus gland, T-cell maturation Restored CD4/CD8…
Thymalin Thymulin receptor agonist. Promotes T-cell maturation in thymic tissue Thymic epithelial cells, T-lymphocyte progenitors 5–10mg per injection 2–3 times weekly Phase 2 trials showing 34% naive T-cell increase over 8 weeks…
Different immune goals require different peptide selections. This comparison helps match peptides to specific situations. Peptide Primary Mechanism Best For Evidence Quality Administration Cost Level Thymosin Alpha-1 T cell enhan…